Duchenne News Tags: REGENXBIO

On October 30, 2025, REGENXBIO Inc. announced the completion of enrollment in the AFFINITY DUCHENNE® pivotal trial of RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy,...

Updates include positive functional, safety and biomarker data for RGX-202, REGENXBIO's potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy.

On March 24, REGENXBIO Inc. shared a Letter to the Duchenne Community announcing updates to their RGX-202 AFFINITY DUCHENNE gene therapy for the treatment of Duchenne muscular dystrophy. To view...

On March 13, 2025, REGENXBIO Inc. reported financial results and recent operational highlights for the fourth quarter and year ended December 31, 2024. Please continue reading to view full updates....

Updates on dosing and more for REGENXBIO's open-label trial of RGX-202 for Duchenne muscular dystrophy.

On November 6, 2024, reported financial results and recent operational highlights for the third quarter ended September 30, 2024. Please continue reading to view their full press release. ROCKVILLE, Md., Nov....

Data updates for Phase I/II AFFINITY DUCHENNE® trial of RGX-202.

REGENXBIO shares a press release detailing updates on its Phase I/II AFFINITY DUCHENNE® trial.

REGENXBIO shares financial results for the first quarter ending March 31, 2024.

REGENXBIO reports additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne.

REGENXBIO announces completion of enrollment in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202.

REGENXBIO announces that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial.

On November 9, 2023, REGENXBIO announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to...